UTHR United Therapeutics Corporation

91.29
-0.73  -1%
Previous Close 92.02
Open 88.86
Price To Book 1.44
Market Cap 4,006,260,737
Shares 43,884,990
Volume 602,249
Short Ratio
Av. Daily Volume 653,958
Stock charts supplied by TradingView

NewsSee all news

  1. United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the fourth quarter and year ended December 31,

  2. United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United

  3. United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®

    RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k)

  4. United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of

  5. United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its fourth quarter and full year 2019 financial results

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - February 24, 2020. sNDA filing due mid-2020.
Tyvaso - INCREASE
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)
Phase 3 data released April 8, 2019 did not meet primary endpoint.
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 2/3 planned.
Aurora-GT - (eNOS gene therapy)
Pulmonary arterial hypertension (PAH)
Phase 3 data released August 8, 2018. Primary endpoint met.
Orenitram
Pulmonary arterial hypertension (PAH)
PDUFA date April 27, 2020.
Trevyent
Pulmonary Arterial Hypertension (PAH)
Approved Dec 20 2013
Oral treprostinil
Pulmonary arterial hypertension (PAH)
Phase 3 ongoing.
Ralinepag ADVANCE OUTCOMES
Pulmonary Arterial Hypertension
Phase 2/3 trial did not meet primary endpoint - February 3, 2020.
Unituxin - DISTINCT
Small cell lung cancer
Phase 1 data due mid-2020.
Treprostinil Technosphere (BREEZE)
Pulmonary Arterial Hypertension (PAH)
Phase 3 trial ongoing.
Inhaled treprostinil
Pulmonary Hypertension associated with chronic obstructive pulmonary disease (PH-COPD).

Latest News

  1. United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the fourth quarter and year ended December 31,

  2. United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United

  3. United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®

    RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k)

  4. United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of

  5. United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its fourth quarter and full year 2019 financial results

  6. United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced that on January 29, 2020, the United States District Court for the District of New

  7. United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 3, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating

  8. United Therapeutics Corporation To Present At The 38th Annual J.P. Morgan Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of

  9. CollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update

    REHOVOT, Israel, Nov. 29, 2019 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the

  10. Correvio Reports Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November

  11. United Therapeutics Corporation Reports Third Quarter 2019 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the quarter ended September 30, 2019. "We are

  12. United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its third quarter 2019 financial results before the

  13. United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement

  14. Respira Therapeutics Regains North America Rights from United Therapeutics to Phase 2 Inhaled Drug-Device Product, RT234, for Pulmonary Hypertension Indications

    ALBUQUERQUE, N.M., Oct. 10, 2019 /PRNewswire/ -- Respira Therapeutics, a clinical-stage specialty pharmaceutical company developing next-generation cardiopulmonary disease-targeted inhalation products, has regained full

  15. United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review